S. Eshleman and J. Jackson, Nevirapine resistance after single dose prophylaxis, AIDS Rev, vol.4, pp.59-63, 2002.

T. Flys, D. Nissley, and C. Claasen, Sensitive Drug???Resistance Assays Reveal Long???Term Persistence of HIV???1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single???Dose NVP: HIVNET 012, The Journal of Infectious Diseases, vol.192, issue.1, pp.24-29, 2005.
DOI : 10.1086/430742

J. Johnson, J. Li, and L. Morris, Emergence of Drug???Resistant HIV???1 after Intrapartum Administration of Single???Dose Nevirapine Is Substantially Underestimated, The Journal of Infectious Diseases, vol.192, issue.1, pp.16-23, 2005.
DOI : 10.1086/430741

S. Eshleman, L. Guay, and A. Mwatha, Comparison of Nevirapine (NVP) Resistance in Ugandan Women 7 Days vs. 6???8 Weeks after Single-Dose NVP Prophylaxis: HIVNET 012, AIDS Research and Human Retroviruses, vol.20, issue.6, pp.595-599, 2004.
DOI : 10.1089/0889222041217518

S. Eshleman, L. Guay, and J. Wang, Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.40, issue.1, pp.24-29, 2005.
DOI : 10.1097/01.qai.0000174656.71276.d6

S. Eshleman, D. Hoover, and S. Chen, Nevirapine (NVP) Resistance in Women with HIV???1 Subtype C, Compared with Subtypes A and D, after the Administration of Single???Dose NVP, The Journal of Infectious Diseases, vol.192, issue.1, pp.30-36, 2005.
DOI : 10.1086/430764

A. National, . Authority, and . Cambodia, Monitoring the Declaration of Commitment?United Nations General Assembly Special Session on HIV, AIDS, 2004.

N. Ly, P. Recordon-pinson, and V. Phoung, Characterization of Mutations in HIV Type 1 Isolates from 144 Cambodian Recently Infected Patients and Pregnant Women Naive to Antiretroviral Drugs, AIDS Research and Human Retroviruses, vol.21, issue.11, pp.971-976, 2005.
DOI : 10.1089/aid.2005.21.971
URL : https://hal.archives-ouvertes.fr/pasteur-01836545

T. Toni, B. Masquelier, and E. Lazaro, Characterization of Nevirapine (NVP) Resistance Mutations and HIV Type 1 Subtype in Women from Abidjan (C??te d'Ivoire) After NVP Single-Dose Prophylaxis of HIV Type 1 Mother-to-Child Transmission, AIDS Research and Human Retroviruses, vol.21, issue.12, pp.1031-1034, 2005.
DOI : 10.1089/aid.2005.21.1031

G. Jourdain, N. Ngo-giang-huong, L. Coeur, and S. , Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy, New England Journal of Medicine, vol.351, issue.3, pp.229-240, 2004.
DOI : 10.1056/NEJMoa041305

M. Chaix, C. Montcho, and D. Ekouevi, Genotypic resistance analysis in women who received intrapartum nevirapine (NVP) associated to a short course of zidovudine (ZDV) to prevent perinatal HIV-1 transmission: The Ditrame Plus ANRS 1201, 11th Conference on Retroviruses and Opportunistic Infections, 2004.

C. Cunningham, M. Chaix, and C. Rekacewicz, Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316, The Journal of Infectious Diseases, vol.186, issue.2, pp.181-188, 2002.
DOI : 10.1086/341300

H. Devereux, M. Youle, M. Johnson, and C. Loveday, Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy, AIDS, vol.13, issue.18, pp.123-127, 1999.
DOI : 10.1097/00002030-199912240-00001

S. Eshleman, G. Becker-pergola, and M. Deseyve, Impact of Human Immunodeficiency Virus Type 1 (HIV???1) Subtype on Women Receiving Single???Dose Nevirapine Prophylaxis to Prevent HIV???1 Vertical Transmission (HIV Network for Prevention Trials 012 Study), The Journal of Infectious Diseases, vol.184, issue.7, pp.914-917, 2001.
DOI : 10.1086/323153

L. Morris, N. Martinson, and C. Pillay, Persistence of nevirapine resistance mutations 6 months following single dose nevirapine, Program and Abstracts of the 15th International AIDS Conference, 2004.

K. Ariyoshi, M. Matsuda, H. Miura, S. Tateishi, K. Yamada et al., Patterns of Point Mutations Associated With Antiretroviral Drug Treatment Failure in CRF01_AE (Subtype E) Infection Differ From Subtype B Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.33, issue.3, pp.336-342, 2003.
DOI : 10.1097/00126334-200307010-00007

L. Hsu, R. Subramaniam, L. Bacheler, and N. Paton, Characterization of Mutations in CRF01_AE Virus Isolates From Antiretroviral Treatment-Naive and -Experienced Patients in Singapore, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.38, issue.1, pp.5-13, 2005.
DOI : 10.1097/00126334-200501010-00002

R. Kantor, D. Katzenstein, and B. Efron, Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration, PLoS Medicine, vol.17, issue.4, p.112, 2005.
DOI : 10.1371/journal.pmed.0020112.sd001